Compare iShares International Treasury Bond ETF (IGOV) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Pfizer Inc — how do they compare? iShares International Treasury Bond ETF trades at $40.6, while Pfizer Inc trades at $24.87 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while iShares International Treasury Bond ETF pays none, and Pfizer Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | PFE | |
|---|---|---|
52-Week High | $43.09 | $28.56 |
52-Week Low | $40.54 | $23.29 |
Market Cap | — | $141.06B |
Volume | — | 29,869,932 |
Sector | — | Health |
Enterprise Value | — | $191.72B |
Dividend Yield | — | 6.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, trading at $40.68, is experiencing a slight decline of 0.22% today amid a bearish technical signal, with moving averages indicating strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins, while recent news highlights significant downside risks from global inflationary pressures affecting its bond holdings.
The outlook for IGOV is cautious due to high duration exposure amplifying capital losses in a rising rate environment. Investment opportunities are limited without clear financial metrics, and risks include persistent energy issues and geopolitical tensions that could further impact performance.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
